OOIR: Observatory of International Research

Papers

(The TQCC of npj Precision Oncology is 12. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-04-01 to 2024-04-01.)

Article	Citations
Machine learning approaches to drug response prediction: challenges and recent progress	159
3D bioprinting for reconstituting the cancer microenvironment	155
Classification and mutation prediction based on histopathology H&E images in liver cancer using deep learning	117
Patient-derived organoids as a predictive biomarker for treatment response in cancer patients	113
Honeybee venom and melittin suppress growth factor receptor activation in HER2-enriched and triple-negative breast cancer	80
Genomic context of NTRK1/2/3 fusion-positive tumours from a large real-world population	77
High expression of ACE2 and TMPRSS2 and clinical characteristics of COVID-19 in colorectal cancer patients	62
PD-L1 immunohistochemistry for canine cancers and clinical benefit of anti-PD-L1 antibody in dogs with pulmonary metastatic oral malignant melanoma	55
Quantitative MRI-based radiomics for noninvasively predicting molecular subtypes and survival in glioma patients	52
Microbiome dysbiosis in lung cancer: from composition to therapy	51
Blood-derived lncRNAs as biomarkers for cancer diagnosis: the Good, the Bad and the Beauty	51
Multiplex bioimaging of single-cell spatial profiles for precision cancer diagnostics and therapeutics	50
Single-cell analysis of gastric pre-cancerous and cancer lesions reveals cell lineage diversity and intratumoral heterogeneity	47
Pan-cancer analysis of SETD2 mutation and its association with the efficacy of immunotherapy	47
GD2 CAR T cells against human glioblastoma	43
The pan-cancer landscape of crosstalk between epithelial-mesenchymal transition and immune evasion relevant to prognosis and immunotherapy response	40
Tumor microenvironment heterogeneity an important mediator of prostate cancer progression and therapeutic resistance	38
Multiplexed drug testing of tumor slices using a microfluidic platform	36
Will polygenic risk scores for cancer ever be clinically useful?	34
Genetic mutation and biological pathway prediction based on whole slide images in breast carcinoma using deep learning	34
Selective KRAS G12C inhibitors in non-small cell lung cancer: chemistry, concurrent pathway alterations, and clinical outcomes	33
Clinical application of a lung cancer organoid (tumoroid) culture system	32
Small cell transformation of ROS1 fusion-positive lung cancer resistant to ROS1 inhibition	32
Dynamic roles of inflammasomes in inflammatory tumor microenvironment	30
The L730V/I RET roof mutations display different activities toward pralsetinib and selpercatinib	30

A tumor microenvironment-specific gene expression signature predicts chemotherapy resistance in colorectal cancer patients	29
Integrated multiomics analysis of hepatoblastoma unravels its heterogeneity and provides novel druggable targets	29
Deep learning for end-to-end kidney cancer diagnosis on multi-phase abdominal computed tomography	28
High TGF-β signature predicts immunotherapy resistance in gynecologic cancer patients treated with immune checkpoint inhibition	28
Structural variant detection in cancer genomes: computational challenges and perspectives for precision oncology	27
Immune microenvironment characterisation and dynamics during anti-HER2-based neoadjuvant treatment in HER2-positive breast cancer	26
A phase I/II study of rovalpituzumab tesirine in delta-like 3—expressing advanced solid tumors	26
Identification of gastric cancer subtypes based on pathway clustering	26
Survival improvement for patients with metastatic colorectal cancer over twenty years	25
Different pathologic responses to neoadjuvant anti-PD-1 in primary squamous lung cancer and regional lymph nodes	25
Durable complete response to neoantigen-loaded dendritic-cell vaccine following anti-PD-1 therapy in metastatic gastric cancer	25
Impressive response to dabrafenib, trametinib, and osimertinib in a metastatic EGFR-mutant/BRAF V600E lung adenocarcinoma patient	24
Cancer-specific immune evasion and substantial heterogeneity within cancer types provide evidence for personalized immunotherapy	24
Pan-cancer analysis of genomic scar patterns caused by homologous repair deficiency (HRD)	23
Bevacizumab improves tumor infiltration of mature dendritic cells and effector T-cells in triple-negative breast cancer patients	23
A blood-based miRNA signature with prognostic value for overall survival in advanced stage non-small cell lung cancer treated with immunotherapy	23
Circulating tumor cell heterogeneity in neuroendocrine prostate cancer by single cell copy number analysis	22
Comprehensive pan-cancer genomic landscape of KRAS altered cancers and real-world outcomes in solid tumors	22
Antibody-drug conjugates in lung cancer: dawn of a new era?	22
Co-occurring genomic alterations and immunotherapy efficacy in NSCLC	21
Validation of a liquid biopsy assay with molecular and clinical profiling of circulating tumor DNA	21
Image analysis reveals molecularly distinct patterns of TILs in NSCLC associated with treatment outcome	20
Comprehensive functional evaluation of variants of fibroblast growth factor receptor genes in cancer	20
A genomic mutation signature predicts the clinical outcomes of immunotherapy and characterizes immunophenotypes in gastrointestinal cancer	20
A tyrosine kinase inhibitor-induced interferon response positively associates with clinical response in EGFR-mutant lung cancer	20
Liquid biopsy mutation panel for non-small cell lung cancer: analytical validation and clinical concordance	20
Single-cell spatial architectures associated with clinical outcome in head and neck squamous cell carcinoma	20
Targeting CDK1 in cancer: mechanisms and implications	20
Cell graph neural networks enable the precise prediction of patient survival in gastric cancer	20
Combined FGFR and Akt pathway inhibition abrogates growth of FGFR1 overexpressing EGFR-TKI-resistant NSCLC cells	19
Efficacy of MEK inhibition in a recurrent malignant peripheral nerve sheath tumor	19
Predictive and prognostic transcriptomic biomarkers in soft tissue sarcomas	19
Self-supervised attention-based deep learning for pan-cancer mutation prediction from histopathology	19
Pan-cancer prognostic genetic mutations and clinicopathological factors associated with survival outcomes: a systematic review	19
A deep learning model for molecular label transfer that enables cancer cell identification from histopathology images	19
Artificial intelligence reveals features associated with breast cancer neoadjuvant chemotherapy responses from multi-stain histopathologic images	18
Prostate cancer polygenic risk score and prediction of lethal prostate cancer	18
Complete response to PD-1 blockade following EBV-specific T-cell therapy in metastatic nasopharyngeal carcinoma	18
Just Add Data: automated predictive modeling for knowledge discovery and feature selection	18
Pre-treatment serum albumin and mutational burden as biomarkers of response to immune checkpoint blockade	18
Super-enhancer in prostate cancer: transcriptional disorders and therapeutic targets	18
Vaginal microbiota, genital inflammation, and neoplasia impact immune checkpoint protein profiles in the cervicovaginal microenvironment	18
Association of mismatch repair status with survival and response to neoadjuvant chemo(radio)therapy in rectal cancer	18
Decreased cytotoxic T cells and TCR clonality in organ transplant recipients with squamous cell carcinoma	18
Targeting the epichaperome as an effective precision medicine approach in a novel PML-SYK fusion acute myeloid leukemia	18
Applications and clinical trial landscape using Toll-like receptor agonists to reduce the toll of cancer	17
The identification and functional analysis of CD8+PD-1+CD161+ T cells in hepatocellular carcinoma	17
Early identification of disease progression in ALK-rearranged lung cancer using circulating tumor DNA analysis	17
Genomic features and tumor immune microenvironment alteration in NSCLC treated with neoadjuvant PD-1 blockade	17
Deep learning for diagnosis of acute promyelocytic leukemia via recognition of genomically imprinted morphologic features	17

Mendelian randomization analyses of genetically predicted circulating levels of cytokines with risk of breast cancer	17
Plasma cell-free RNA profiling distinguishes cancers from pre-malignant conditions in solid and hematologic malignancies	17
Clinical response to nivolumab in an INI1-deficient pediatric chordoma correlates with immunogenic recognition of brachyury	17
Crizotinib in patients with tumors harboring ALK or ROS1 rearrangements in the NCI-MATCH trial	17
Characterizing advanced breast cancer heterogeneity and treatment resistance through serial biopsies and comprehensive analytics	17
Urine cell-free DNA multi-omics to detect MRD and predict survival in bladder cancer patients	16
Accurate surgical navigation with real-time tumor tracking in cancer surgery	16
Inflation of tumor mutation burden by tumor-only sequencing in under-represented groups	16
Feasibility and first reports of the MATCH-R repeated biopsy trial at Gustave Roussy	16
Circulating tumor cell copy-number heterogeneity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitors	16
Small extracellular vesicle PD-L1 in cancer: the knowns and unknowns	16
Molecular pathogenesis of desmoid tumor and the role of γ-secretase inhibition	16
A subset of lung cancer cases shows robust signs of homologous recombination deficiency associated genomic mutational signatures	16
Genomic characterization and outcome evaluation of kinome fusions in lung cancer revealed novel druggable fusions	16
Acetylation of ELF5 suppresses breast cancer progression by promoting its degradation and targeting CCND1	15
The Aurora kinase/β-catenin axis contributes to dexamethasone resistance in leukemia	15
Progression of prostate carcinoma is promoted by adipose stromal cell-secreted CXCL12 signaling in prostate epithelium	15
A computational method for prioritizing targeted therapies in precision oncology: performance analysis in the SHIVA01 trial	15
Artificial intelligence for the next generation of precision oncology	15
Splice-switching of the insulin receptor pre-mRNA alleviates tumorigenic hallmarks in rhabdomyosarcoma	15
Clinical, genetic and pharmacological data support targeting the MEK5/ERK5 module in lung cancer	15
An international working group consensus report for the prioritization of molecular biomarkers for Ewing sarcoma	15
Association of pro-inflammatory soluble cytokine receptors early during hepatocellular carcinoma stereotactic radiotherapy with liver toxicity	15
Pentraxin 3 is a stromally-derived biomarker for detection of pancreatic ductal adenocarcinoma	15
Secondary IDH1 resistance mutations and oncogenic IDH2 mutations cause acquired resistance to ivosidenib in cholangiocarcinoma	15
Harnessing the immunotherapeutic potential of CDK4/6 inhibitors in melanoma: is timing everything?	14
Usability of deep learning and H&E images predict disease outcome-emerging tool to optimize clinical trials	14
Rare deleterious germline variants and risk of lung cancer	14
Spatially variant immune infiltration scoring in human cancer tissues	14
HER3 activation contributes toward the emergence of ALK inhibitor-tolerant cells in ALK-rearranged lung cancer with mesenchymal features	13
Targeted biologic inhibition of both tumor cell-intrinsic and intercellular CLPTM1L/CRR9-mediated chemotherapeutic drug resistance	13
Real-world data analyses unveiled the immune-related adverse effects of immune checkpoint inhibitors across cancer types	13
On-treatment measurements of circulating tumor DNA during FOLFOX therapy in patients with colorectal cancer	13
Imaging immunity in patients with cancer using positron emission tomography	13
Overcoming resistance to BRAFV600E inhibition in melanoma by deciphering and targeting personalized protein network alterations	13
Characterization of evolution trajectory and immune profiling of brain metastasis in lung adenocarcinoma	12
Multiscale-omic assessment of EWSR1-NFATc2 fusion positive sarcomas identifies the mTOR pathway as a potential therapeutic target	12
Circulating stromal cells in resectable pancreatic cancer correlates to pathological stage and predicts for poor clinical outcomes	12
Immunosuppression for immune-related adverse events during checkpoint inhibition: an intricate balance	12
Computer extracted gland features from H&E predicts prostate cancer recurrence comparably to a genomic companion diagnostic test: a large multi-site study	12